ReSViNet 2023 Data Reinforce AstraZeneca ’s Commitment to Help Prevent Respiratory Syncytial Virus in Infants

Beyfortus continues to demonstrate consistent protection against RSV disease through the RSV season New Canadian analysis demonstrates Synagis to be highly cost-effective in 29-35 weeks gestational age infants 21 February 2023 --...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials